[go: up one dir, main page]

DK1401413T3 - Anvendelse af tyrosinkinaseinhibitorer til behandling af allergiske sygdomme - Google Patents

Anvendelse af tyrosinkinaseinhibitorer til behandling af allergiske sygdomme

Info

Publication number
DK1401413T3
DK1401413T3 DK02755512T DK02755512T DK1401413T3 DK 1401413 T3 DK1401413 T3 DK 1401413T3 DK 02755512 T DK02755512 T DK 02755512T DK 02755512 T DK02755512 T DK 02755512T DK 1401413 T3 DK1401413 T3 DK 1401413T3
Authority
DK
Denmark
Prior art keywords
treatment
tyrosine kinase
allergic diseases
kinase inhibitors
inhibitor
Prior art date
Application number
DK02755512T
Other languages
Danish (da)
English (en)
Inventor
Alain Moussy
Jean-Pierre Kinet
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Application granted granted Critical
Publication of DK1401413T3 publication Critical patent/DK1401413T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK02755512T 2001-06-29 2002-06-28 Anvendelse af tyrosinkinaseinhibitorer til behandling af allergiske sygdomme DK1401413T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30140801P 2001-06-29 2001-06-29
PCT/IB2002/003297 WO2003002106A2 (fr) 2001-06-29 2002-06-28 Utilisation d'inhibiteurs de tyrosine kinase dans le traitement de maladies allergiques

Publications (1)

Publication Number Publication Date
DK1401413T3 true DK1401413T3 (da) 2007-03-26

Family

ID=23163215

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02755512T DK1401413T3 (da) 2001-06-29 2002-06-28 Anvendelse af tyrosinkinaseinhibitorer til behandling af allergiske sygdomme

Country Status (11)

Country Link
US (1) US7700610B2 (fr)
EP (1) EP1401413B1 (fr)
JP (1) JP2004537536A (fr)
AT (1) ATE345839T1 (fr)
CA (1) CA2452371A1 (fr)
CY (1) CY1106011T1 (fr)
DE (1) DE60216281T2 (fr)
DK (1) DK1401413T3 (fr)
ES (1) ES2274993T3 (fr)
PT (1) PT1401413E (fr)
WO (1) WO2003002106A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2452368A1 (fr) 2001-06-29 2003-01-09 Ab Science Nouveaux inhibiteurs selectifs puissants et non toxiques de c-kit
WO2003004007A2 (fr) 2001-06-29 2003-01-16 Ab Science Utilisation d'inhibiteurs de tyrosine kinases pour traiter les maladies intestinales inflammatoires (mii)
DK1401413T3 (da) 2001-06-29 2007-03-26 Ab Science Anvendelse af tyrosinkinaseinhibitorer til behandling af allergiske sygdomme
EP1401415B1 (fr) * 2001-06-29 2006-06-21 AB Science Utilisation de derives de la n-phenyl-2-pyrimidine-amine destines au traitement de maladies inflammatoires
EP1401412A2 (fr) * 2001-06-29 2004-03-31 AB Science Utilisation d'inhibiteurs de materiel c, puissants, selectifs et non toxiques pour traiter l'angiogenese tumorale
ATE401079T1 (de) * 2001-06-29 2008-08-15 Ab Science Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
US20040242601A1 (en) * 2001-09-20 2004-12-02 Alain Moussy Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
ATE401078T1 (de) * 2001-09-20 2008-08-15 Ab Science Die verwendung von c-kithemmern zur förderung des haarwuchses
WO2003072090A2 (fr) * 2002-02-27 2003-09-04 Ab Science Utilisation d'inhibiteurs de tyrosine kinase pour le traitement de troubles du snc
US20060052387A1 (en) * 2002-06-26 2006-03-09 Marsh Clay B Organic compounds
EP1525200B1 (fr) 2002-08-02 2007-10-10 AB Science 2-(3-aminoaryl)amino-4-aryl-thiazoles et leur utilisation en tant que inhibiteurs de c-kit
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
ATE465731T1 (de) 2003-10-23 2010-05-15 Ab Science 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer
WO2005115385A1 (fr) * 2004-05-24 2005-12-08 Ab Science Utilisation d'inhibiteurs de c-kit pour le traitement de l'acne
AU2006231929B2 (en) 2005-04-04 2012-09-06 Ab Science Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
HRP20110709T1 (hr) 2007-02-13 2011-11-30 Ab Science Postupak sinteze spojeva 2-aminotioazola kao inhibitora kinaza
EP2434961B1 (fr) 2009-05-29 2015-01-14 Xlumena, Inc. Appareil et méthode de déploiement d'une endoprothèse à travers des couches de tissu adjacent
CN103717591B (zh) 2011-07-27 2016-08-24 Ab科学有限公司 作为选择性蛋白激酶(c-kit)抑制剂的噁唑和噻唑衍生物
US20150044288A1 (en) 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558653A (en) 1968-05-20 1971-01-26 Searle & Co Dialkylaminoalkyl-indolines
US3725403A (en) 1970-10-20 1973-04-03 Squibb & Sons Inc Benzothiazine derivatives
US4438267A (en) 1980-11-11 1984-03-20 Daluge Susan M Monoheteroring compounds and their use
GB8913708D0 (en) 1989-06-14 1989-08-02 Unilever Plc Cosmetic composition
US5308839A (en) 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
TW225528B (fr) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
JP2000508894A (ja) 1996-04-10 2000-07-18 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド 細胞外／上皮増殖因子ｈｃａｂａ５８ｘ
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
AU6163398A (en) 1997-02-11 1998-08-26 Merck & Co., Inc. Identification of inhibitors of protein tyrosine kinase 2
CA2283961A1 (fr) 1997-03-19 1998-09-24 Basf Aktiengesellschaft Pyrrolo [2,3] pyrimidines et leur utilisation comme inhibiteurs de la tyrosine kinase
WO1998050356A1 (fr) 1997-05-07 1998-11-12 Sugen, Inc. Derives de 2-indolinone utilises en tant que modulateurs de l'activite de la proteine kinase
WO1998055152A1 (fr) 1997-06-06 1998-12-10 Baylor College Of Medicine Mecanisme secretoire des mastocytes utilise comme cible en vue du developpement de medicaments antiallergiques
US6114371A (en) 1997-06-20 2000-09-05 Sugen, Inc. 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
WO1999011643A1 (fr) 1997-09-02 1999-03-11 Du Pont Pharmaceuticals Company Pyridines a cycle fusionne et a substitution heterocyclyle, antagonistes du facteur de liberation de la cortitropine (crf), utiles dans le traitement des troubles lies au snc et au stress
US6133305A (en) 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US5952374A (en) 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
EP1082122A4 (fr) 1998-05-27 2003-04-09 Sherwood L Gorbach Isoflavonoides utiles dans le traitement et la prevention de maux de tete du type migraine
CA2314156C (fr) 1998-05-29 2010-05-25 Sugen, Inc. Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole
DE19824922A1 (de) 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
RS50087B (sr) 1998-06-19 2009-01-22 Pfizer Products Inc., Pirolo (2,3-d) pirimidin jedinjenja
PT1105136E (pt) 1998-08-13 2007-12-03 Novartis Ag Método para tratar doenças oculares neovasculares
DE19844003A1 (de) 1998-09-25 2000-03-30 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
WO2000040971A1 (fr) 1998-12-31 2000-07-13 Sugen, Inc. Pyk2 (raftk) et inflammation
US6498176B1 (en) 1999-03-04 2002-12-24 Smithklinebeecham Corporation 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
IL144897A0 (en) 1999-03-12 2002-06-30 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
JP2002540096A (ja) 1999-03-24 2002-11-26 スージェン・インコーポレーテッド キナーゼ阻害剤としてのインドリノン化合物
US6989248B2 (en) 1999-05-06 2006-01-24 The Trustees Of Columbia University In The City Of New York Methods of use of compounds which inhibit the stem cell signaling pathway
EP1206265B1 (fr) 1999-06-30 2003-11-12 Merck & Co., Inc. Composes inhibiteurs de la src kinase
WO2001016130A1 (fr) 1999-08-27 2001-03-08 Boehringer Ingelheim Pharma Kg Indolinones substituees utilisees comme inhibiteurs de la tyrosine kinase
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
ES2267605T3 (es) * 1999-12-22 2007-03-16 Sugen, Inc. Uso de compuestos de indolinona para la fabricacion de productos farmaceuticos destinados a modular la funcion de la c-kit-tirosina-proteina-quinasa.
WO2001047950A2 (fr) 1999-12-23 2001-07-05 Universite De Geneve Signal de tri basolateral et inhibiteurs correspondants
US6339100B1 (en) 1999-12-29 2002-01-15 The Trustees Of Columbia University In The City Of New York Methods for inhibiting mastocytosis
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
US6420382B2 (en) * 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1261607B1 (fr) 2000-03-01 2008-11-12 Janssen Pharmaceutica N.V. Derives de thiazolyle 2,4-disubstitue
US7087608B2 (en) 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
KR100885129B1 (ko) * 2000-10-27 2009-02-23 노파르티스 아게 위장관의 기질 종양의 치료
GEP20063915B (en) 2000-11-17 2006-09-11 Bristol Myers Squibb Co PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
CA2432114A1 (fr) 2000-12-20 2002-07-18 Sugen, Inc. Indolinones 4-aryl substituees
AU2002254152A1 (en) 2001-03-08 2002-09-24 Millennium Pharmaceuticals (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases
GB0108606D0 (en) 2001-04-05 2001-05-23 Novartis Ag Organic compounds
CA2446939C (fr) * 2001-05-16 2005-08-02 Matthias Stein-Gerlach Derives de pyridylpyrimidine utilises comme composes actifs contre des infections et des maladies a prions
EP1401411A2 (fr) 2001-06-29 2004-03-31 AB Science Utilisation d'inhibiteurs de la tyrosine kinase dans le traitement de la perte osseuse
US20030091974A1 (en) 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
ATE401079T1 (de) 2001-06-29 2008-08-15 Ab Science Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
JP2005503361A (ja) 2001-06-29 2005-02-03 アブ サイエンス 肥満細胞症治療のための強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤の使用
DK1401413T3 (da) 2001-06-29 2007-03-26 Ab Science Anvendelse af tyrosinkinaseinhibitorer til behandling af allergiske sygdomme
US20040259892A1 (en) 2001-06-29 2004-12-23 Alain Moussy Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms)
WO2003004007A2 (fr) 2001-06-29 2003-01-16 Ab Science Utilisation d'inhibiteurs de tyrosine kinases pour traiter les maladies intestinales inflammatoires (mii)
EP1401415B1 (fr) 2001-06-29 2006-06-21 AB Science Utilisation de derives de la n-phenyl-2-pyrimidine-amine destines au traitement de maladies inflammatoires
EP1401412A2 (fr) 2001-06-29 2004-03-31 AB Science Utilisation d'inhibiteurs de materiel c, puissants, selectifs et non toxiques pour traiter l'angiogenese tumorale
CA2452368A1 (fr) 2001-06-29 2003-01-09 Ab Science Nouveaux inhibiteurs selectifs puissants et non toxiques de c-kit
CA2457799C (fr) 2001-08-21 2014-05-27 Ventana Medical Systems, Inc. Methode et essai de quantification permettant d'evaluer l'etat du systeme c-kit/scf/pakt
US20060204459A1 (en) 2001-09-20 2006-09-14 Alain Moussy Use of tyrosine inhibitors for whitening human skin and treating melanocyted dysfunction associated diseases
US20040242601A1 (en) 2001-09-20 2004-12-02 Alain Moussy Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
ATE401078T1 (de) 2001-09-20 2008-08-15 Ab Science Die verwendung von c-kithemmern zur förderung des haarwuchses
DE60225590T2 (de) 2001-09-20 2008-09-25 Ab Science C-kithemmer zur behandlung von bakteriellen infektionen
EP1469810A4 (fr) 2002-01-04 2009-01-14 Univ Rockefeller Compositions et procedes de prevention et de traitement de troubles lies au peptide beta-amyloide
EP1467981A1 (fr) 2002-01-25 2004-10-20 Kylix Pharmaceuticals B.V. (thia-/oxa-/pyra) zoles substitues 4(hetero-) aryle pour inhibition de tie-2
WO2003072090A2 (fr) 2002-02-27 2003-09-04 Ab Science Utilisation d'inhibiteurs de tyrosine kinase pour le traitement de troubles du snc
US20050089838A1 (en) 2002-06-28 2005-04-28 Alain Moussy Method for identifying compounds that specifically deplete mast cells
EP1525200B1 (fr) 2002-08-02 2007-10-10 AB Science 2-(3-aminoaryl)amino-4-aryl-thiazoles et leur utilisation en tant que inhibiteurs de c-kit
US20060275769A1 (en) 2003-01-06 2006-12-07 Oregon Health & Science University Methods of treatment and diagnosis of kaposi's sarcoma (ks) and ks related diseases

Also Published As

Publication number Publication date
US7700610B2 (en) 2010-04-20
EP1401413B1 (fr) 2006-11-22
DE60216281T2 (de) 2007-07-05
WO2003002106A2 (fr) 2003-01-09
DE60216281D1 (de) 2007-01-04
EP1401413A2 (fr) 2004-03-31
CY1106011T1 (el) 2011-04-06
US20040259893A1 (en) 2004-12-23
CA2452371A1 (fr) 2003-01-09
WO2003002106A3 (fr) 2003-05-30
PT1401413E (pt) 2007-02-28
JP2004537536A (ja) 2004-12-16
ES2274993T3 (es) 2007-06-01
ATE345839T1 (de) 2006-12-15

Similar Documents

Publication Publication Date Title
DK1401413T3 (da) Anvendelse af tyrosinkinaseinhibitorer til behandling af allergiske sygdomme
ATE404202T1 (de) Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung
WO2003002114A3 (fr) Utilisation d'inhibiteurs de c-kit puissants, selectifs et non toxiques dans le traitement de la mastocytose
DK1401415T3 (da) Anvendelse af N-phenyl-2-pyrimidinamin-derivater til behandling af inflammatoriske sygdomme
CY1105930T1 (el) Χρηση αναστολεων c-kit για θepαπεια ασθενειων φλεγμονωδους εντερου (ibd)
WO2003002107A3 (fr) Utilisation d'inhibiteurs de tyrosine kinase dans le traitement de la sclerose en plaques
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ATE401079T1 (de) Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
DK1478380T3 (da) Anvendelse af tyrosinkinase-inhibitorer til behandling af CNS-lidelser
EA200300906A1 (ru) Новые спиротрициклические производные и их применение в качестве ингибиторов фосфодиэстеразы-7
ATE388711T1 (de) C-kithemmer zur behandlung von bakteriellen infektionen
ATE453707T1 (de) Verfahren zur isolierung von mesenchymalen stammzellen des haarfollikels
WO2003002105A3 (fr) Utilisation d'inhibiteurs de la tyrosine kinase dans le traitement de la perte osseuse
ATE401078T1 (de) Die verwendung von c-kithemmern zur förderung des haarwuchses
WO2003004006A8 (fr) Utilisation d'inhibiteurs de materiel c, puissants, selectifs et non toxiques pour traiter l'angiogenese tumorale
WO2004096225A3 (fr) Utilisation d'inhibiteurs de tyrosine kinase pour le traitement de l'ischemie cerebrale
DE60323613D1 (de) Verwendung von tyrosinkinase-hemmern zur behandlung von erkrankungen im zusammenhang mit substanzgebrauch
WO2005102346A3 (fr) Utilisation des inhibiteurs de c-kit pour le traitement de la fibrose
ATE444762T1 (de) Therapeutische zusammenseztungen zur toleranzinduktion